(Q39191241)

9 September 2017

title

Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model (English)

1 reference

9 September 2017

0 references

1 reference

1 reference

Eric J Snijder

10

0 references

Stanley Perlman

object named as

Stanley Perlman

9

0 references

Heinz Feldmann

8

object named as

Heinz Feldmann

1 reference

9 September 2017

5

Craig Fett

1 reference

9 September 2017

2

Darryl Falzarano

1 reference

9 September 2017

6

Cynthia Martellaro

1 reference

Jessika C Zevenhoven-Dobbe

9 September 2017

3

object named as

Jessika C Zevenhoven-Dobbe

1 reference

9 September 2017

7

Clara C Posthuma

1 reference

9 September 2017

Adriaan H de Wilde

1

1 reference

9 September 2017

Corrine Beugeling

4

1 reference

9 September 2017

publication date

10 November 2016

1 reference

9 September 2017

1 reference

9 September 2017

volume

228

1 reference

9 September 2017

page(s)

7-13

1 reference

Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Human coronavirus NL63 replication is cyclophilin A-dependent and inhibited by non-immunosuppressive cyclosporine A-derivatives including Alisporivir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Structural and biochemical characterization of the human cyclophilin family of peptidyl-prolyl isomerases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Update on alisporivir in treatment of viral hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Acute Management and Long-Term Survival Among Subjects With Severe Middle East Respiratory Syndrome Coronavirus Pneumonia and ARDS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Porcine epidemic diarrhea virus induces caspase-independent apoptosis through activation of mitochondrial apoptosis-inducing factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Suppression of viral RNA binding and the assembly of infectious hepatitis C virus particles in vitro by cyclophilin inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Emerging picture of host chaperone and cyclophilin roles in RNA virus replication.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

A three-dimensional model to analyze drug-drug interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Mechanism of resistance of hepatitis C virus replicons to structurally distinct cyclophilin inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

The mechanism of action of cyclosporin A and FK506

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

IFN-α2a or IFN-β1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Suppression of feline coronavirus replication in vitro by cyclosporin A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Cyclosporin A inhibits the replication of diverse coronaviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Cyclophilin inhibitors block arterivirus replication by interfering with viral RNA synthesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Epithelial differentiation is a determinant in the production of eotaxin-2 and -3 by bronchial epithelial cells in response to IL-4 and IL-13

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Reverse genetics of SARS-related coronavirus using vaccinia virus-based recombination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIRUSRES.2016.11.011

Interferon-β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell-based assays

7 January 2021

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27840112

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.VIRUSRES.2016.11.011

1 reference

9 September 2017

0 references

1 reference